Preclinical formulation for the pharmacokinetics and efficacy of GBO-006, a selective polo like kinase 2 (PLK2) inhibitor for the treatment of triple negative breast cancer. ADMET DMPK. 2016;4(4):314-326. doi:10.5599/admet.4.4.341